Mineko Yasuo

Tokyo Women's Medical University, Edo, Tōkyō, Japan

Are you Mineko Yasuo?

Claim your profile

Publications (2)4.38 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of a humanized anti-human leukocyte antigen-DR monoclonal antibody, IMMU-114, on the allogeneic immune response was investigated in vitro. Responder peripheral blood mononuclear cells were cocultured with inactivated self or allogeneic stimulator peripheral blood mononuclear cells in the presence of control antibody or IMMU-114. Thymidine incorporation rates were then measured. Phenotypic changes in peripheral blood mononuclear cells and the intracellular Th1-type cytokines interleukin-2, interferon-γ, and tumor necrosis factor-α were analyzed using flow cytometry. The concentrations of interleukin-2, interferon-γ, and tumor necrosis factor-α in the mixed lymphocyte reaction culture medium were measured. Thymidine incorporation rates at a 1:1 responder/stimulator ratio of allogeneic, allogeneic + IMMU-114, self, and self + IMMU-114 were 22,080.7 ± 602.4, 2,254.5 ± 118.1, 1,284.0 ± 227.8, and 494.5 ± 27.5 cpm, respectively (P = .038). IMMU-114 decreased the frequencies of human leukocyte antigen-DR-expressing CD16+56+ NK cells, CD19+ B cells, and CD3+25+ activated T cells. Intracellular cytokine assay and measurement of Th1-type cytokines in the mixed lymphocyte reaction culture medium revealed that IMMU-114 significantly decreased the titers of interleukin-2, interferon-γ, and tumor necrosis factor-α. IMMU-114 significantly suppresses the allogeneic immune response in vitro, partly through inhibition of the Th1 response.
    American journal of surgery 05/2012; 204(4):527-34. · 2.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of an anti-human leukocyte antigen-DR (MHC class II) humanized monoclonal antibody, IMMU-114, against the human to bovine cellular response was investigated. Human peripheral mononuclear cells (PBMCs) were cocultured with inactivated self-PBMCs (Self), bovine PBMCs with control antibody (Xeno), or bovine PBMCs with IMMU-114 (IMMU-114). Cellular responses were investigated by thymidine incorporation assay, CFSE (carboxyfluorescein diacetate succinimidyl ester)-mixed lymphocyte reaction, and cytokine production in culture medium. Thymidine incorporation rates at a 1:1 responder to stimulator ratio for Xeno + control antibody, Xeno + IMMU-114, Self + control antibody, and Self + IMMU-114 were 14201.3 ± 1968.4, 513.0 ± 49.5, 952.7 ± 128.7, and 423.3 ± 138.8 cpm, respectively (P = 0.032). Those at a 1:2 ratio were 6518.0 ± 690.1, 896.6 ± 92.9, 1051.0 ± 123.6, and 736.0 ± 35.6 cpm, respectively (P = 0.036). CFSE-mixed lymphocyte reaction demonstrated that the frequencies of CFSE-low, CD4(+), and CD25(+) activating T cells in Self, Xeno, and IMMU-114 were 0.27 ± 0.04%, 3.65 ± 0.53%, and 1.23 ± 0.15%, respectively (P = 0.027). Cytokine production in culture medium indicated that IMMU-114 decreased Th1-type cytokines, including interleukin-2, interferon-γ, and tumor necrosis factor-α. IMMU-114 effectively suppresses human to bovine cellular responses. The mechanism involves direct inhibition of the interaction between class II human leukocyte antigen-DR-positive cells and CD4(+) T cells, and indirect suppression of Th1 cytokine production.
    Journal of Surgical Research 04/2012; 178(1):472-7. · 2.02 Impact Factor